We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...

Q1 2025 insights from Corvus Pharmaceuticals highlight promising soquelitinib trial results, extended funding, and plans for Phase 2 trials.

Moody’s Ratings has upgraded the long-term issuer rating and senior unsecured ratings of Sanofi (NASDAQ:SNY) from A1 to Aa3.

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising pipeline developments and a strong cash position.

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

Patients who are immunocompromised still can receive a variety of vaccinations based on their specific needs, Cassandra ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Corvus Pharmaceuticals Inc (CRVS) reports a significant net income boost and promising trial outcomes, despite increased R&D expenses and competitive challenges.

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

The banning of pharmaceutical advertisements is not an assault on free speech. Big Pharma cannot be trusted with the health of Americans.